Rahmer Peter sold $954K of RLAY
Rahmer Peter (See remarks) sold 50,000 shares of Relay Therapeutics, Inc. (RLAY) at $19.09 ($0.95M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is pre-arranged under a Rule 10b5-1 plan, which generally makes it less informative about management’s forward view than unscheduled selling.
Market read
Traders may note the insider sale for sentiment monitoring, but the 10b5-1 framing suggests limited actionable fundamental impact.
What to watch
The article does not provide context on total compensation, prior holdings changes, or whether other insiders sold/bought around the same period.
Background
The article is a SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics disclosed an officer open-market sale of 50,000 shares at $19.09 on June 30 under a 10b5-1 plan.
Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.
The filing is a Form 4 insider transaction, but the article specifies a 10b5-1 pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by liquidity needs or tax planning, so the market may overreact to the headline without a fundamental catalyst.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderRahmer Peter
Officer who sold 50,000 shares in an open-market transaction under a 10b5-1 plan.